The hydroxyethylurea human immunodeficiency virus type 1 (HIV-1) protease inhibitors SC-55389A and SC-52151 were used to select drug-resistant variants in vitro. One clinical HIV-1 strain (89-959) and one laboratory HIV-1 strain (LAI) were passaged in peripheral blood mononuclear cells or CEMT4 cells in the presence of SC-55389A. Resistant isolates from both strains consistently had a mutation to serine for asparagine at amino acid 88 (N88S) in the protease gene either alone or in combination with a change to phenylalanine at position 10. The N88S mutation, recreated by oligonucleotide-mediated site-directed mutagenesis in HXB2, was sufficient to confer resistance to SC-55389A. In contrast, SC-52151-resistant variants selected from the monocytotropic strain SF162 had multiple substitutions in the protease gene (I11V, M46I, F53L, A71V, and N88D), and the N88D mutation, re-created by oligonucleotide-mediated site-directed mutagenesis in HXB2, did not confer resistance to SC-52151. The potencies of L735,524 and Ro31-8959 were not reduced when these compounds were assayed against variants with either the N88S or N88D substitution. Position 88 is in a helix that lies behind the substrate binding pocket and may indirectly influence inhibitor binding through interactions with the amino acid at position 31. The selected mutations were persistent in the viral populations after more than 20 passages in the absence of drugs. Passaging of virus first in SC-55389A alone and then in combination with SC-52151 resulted in the accumulation of more mutations in the protease gene (L10F, D35E, D37M, I47V, I54L, A71V, V82I, and S88D) and in the selection of a variant that was cross-resistant to multiple protease inhibitors. These results indicate that a mutation in the HIV-1 protease at a position that is located outside of the substrate binding pocket confers resistance to a protease inhibitor and that mutations in the protease gene accumulate with increasing selection pressure and can persist in the absence of selection pressure.
Human immunodeficiency virus (HIV-1) particles mature as they bud from the envelope of infected cells. This process is mediated by an aspartyl protease, which cleaves the gag polyprotein into the core structural proteins, and inhibition of the protease results in the formation of immature, noninfectious particles. Successful development of potent protease inhibitors that suppress HIV replication provide alternate therapies for AIDS patients. However, variants of HIV-1 that are resistant to various protease inhibitors have been identified after the treatment of large viral populations in vitro and under conditions of high viral burden in vivo (7, 18, 25) . The pathogenesis of HIV infection and the patterns of protease mutations due to selective antiviral pressure must be understood in order to devise long-term effective treatment strategies.
The emergence of HIV-1 variants that are resistant to antiviral drugs is not unexpected because reverse transcriptase (RT) has an inherently high error rate and no proofreading mechanism (13) . Therefore, many variants occur in any large population (15; unpublished data). In the presence of selective pressure, such as a specific enzyme inhibitor (e.g., a protease inhibitor), genetic variants that are resistant to the inhibitors will have selective advantages and will eventually predominate in the population (4) . The many amino acid (aa) changes that have been observed after selection with various protease inhibitors are distributed throughout the protease sequence, although certain aa positions appear to be more variable than others (6, 7) . Depending on the inhibitor used and the genetic background of the viral population in the selection, different combinations of mutations will emerge as the dominant genotype in the population. Some mutated residues are located adjacent to the pocket in the protease molecule where inhibitors bind, while others are located outside of the binding pocket. These latter remote sites are of two types: those which confer resistance, such as L90M (14) and N88S (described herein), and those that have not yet been shown to affect resistance, such as those at positions 71 and 63 (3, 17) . The mechanism by which substitutions at residues that do not border the binding pocket confer resistance is not known; however, they may cause conformational perturbations that affect the enzyme in ways that are unrelated to direct binding of the inhibitor (3, 9) .
In this report we describe in vitro selections that were made to identify mutations associated with resistance to two hydroxyethylurea inhibitors, SC-55389A and SC-52151 (2, 11) . Selections were performed with three different viral strains reflecting laboratory (strain LAI), clinical (strain 89-959), and monocytotropic (strain SF162) backgrounds. The roles of these mutations were investigated by re-creating them by oligonucleotide-mediated site-directed mutagenesis in a uniform genetic background. Mutants were also passaged without drugs to test for the persistence of the mutations in the absence of selection pressure. Finally, we evaluated the potential for a combination of two protease inhibitors to suppress the emergence of viral variants that were resistant to both drugs by testing the capacity of a mutant that was resistant to SC-55389A to grow in the presence of both SC-55389A and SC-52151. Our results include the first demonstration that a mutation to serine at position 88 in the HIV-1 protease can confer resistance to a protease inhibitor.
MATERIALS AND METHODS
HIV protease inhibitors. SC-52151, SC-55389A, SC-414, L735,524 (indinavir), and Ro31-8959 (saquinavir) were synthesized at Searle (St. Louis, Mo., and Skokie, Ill.). The chemical structures of SC-52151, SC-55389A, and SC-414 ( Fig.  1 ) have been described previously (10, 11) . Zidovudine (AZT) was purchased from Burroughs Wellcome.
Selection of drug-resistant variants. SC-55389A was used to select for resistant variants in two viral strains. A clinical strain, 89-959 (generous gift of Max Arens, Washington University Medical School, St. Louis, Mo.), was grown in freshly isolated peripheral blood mononuclear cells (PBMCs) in the presence of 1 M SC-55389A (10 times the 50% effective concentration [EC 50 ]) or without drug. The virus was passaged weekly with additions of fresh PBMCs. Selections with strain LAI were made by growing the virus in CEM cells in escalating concentrations of SC-55389A beginning at 50 nM (1.5 times the EC 50 ) and doubling the concentration at each weekly passage when viral growth in the culture was abundant. If viral growth was poor, the culture was passaged one or two times with the same drug concentration before escalation of the drug concentration was resumed. The highest concentration of drug used against LAI was 16 M.
Strain SF162 (AIDS Research and Reference Reagent Program) was grown in PBMCs in the presence or absence of SC-52151 and was passaged weekly, with fresh PBMCs added to the culture. The starting concentration of drug was 20 nM (the mean EC 50 for laboratory strains). When significant viral replication was measured, the drug concentration was doubled during passaging. The highest concentration of drug used was 1 M. After a resistance phenotype was identified in strain SF162, the culture was passaged in the absence of drug (untreated [UT] culture).
Supernatants were periodically sampled from cultures of all three strains, passed through 0.22-m-pore-size filters, and frozen at Ϫ80ЊC prior to use in dose-response assays. At the same time, cell pellets were saved for analysis of viral DNA. After a resistance phenotype was identified in strain SF162, it was FIG. 1. Chemical structures of SC-52151, SC-55389A, and SC-414. Crystal structures of the HIV protease complexed with SC-55389A and with more than 10 other inhibitors in this series (11) demonstrate that the P1Ј and P2Ј groups are flipped; the P1Ј group of a hydroxyethylurea inhibitor (isobutyl in SC-52151; isoamyl in SC-55389A) is bound at the S2Ј subsite of the enzyme, with P2Ј (t-butyl in both inhibitors) bound at S1Ј.
FIG. 2.
Scheme for selection of resistant HIV-1 variants after passaging in the presence of protease inhibitors. Selections were made with three different strains that reflect clinical (89-959), monocytotropic (SF162), and laboratory (LAI) backgrounds. After a resistance phenotype was identified in strain SF162, it was passaged in the absence of drug (UT). After a resistance phenotype was identified in strain 89-959, the culture was split into two portions. One portion was passaged without drug, and the other was passaged in both drugs (SC-55389A and SC-52151).
passaged without drug (Fig. 2) . After a resistance phenotype was identified in strain 89-959, the culture was split into two portions. One portion was passaged in the absence of drug (UT), and the other was passaged in escalating concentrations of both SC-55389A and SC-52151. The highest concentration used was 8 M for each drug. When drug concentrations were 1 M or greater in cultures of 89-959, it was possible to "cure" the viral infection in a single passage because this strain does not grow to high titers. To maintain large viral populations during selections at concentrations higher than 1 M, the cultures were grown in reduced concentrations of drugs on alternate weeks. The reduced concentration was one-fourth that used during the week when the higher concentrations were present.
Sequence analysis of protease. Proviral DNA of the protease gene was amplified by PCR and was used for sequencing or cloning. DNAs from strains 89-959 and SF162 were cloned and sequenced as described by Potts et al. (21) . Briefly, infected cells were lysed and extracted with phenol-chloroform-isoamyl alcohol, and the DNA was precipitated. A 700-bp fragment encompassing the protease gene was amplified by PCR, digested with restriction endonucleases, and subcloned into M13mp18. Double-stranded DNA was sequenced by using fluorescent dye-labelled terminators (Applied Biosystems, Inc.). DNA from strain LAI was directly cycle sequenced by using Taq (Perkin-Elmer Cetus) and was subjected to electrophoresis and autoradiography.
Dose-response assays. The effects of drugs on viral replication were measured in cultures of infected cells grown with different drug concentrations. Drugs were serially diluted 1:2 in 96-well plates, with three or four replicates per assay. Cells infected at a multiplicity of infection of 0.02 were added to the drug solutions, and the cultures were incubated at 37ЊC at 5% CO 2 . Two different assays, the RT and p24 antigen assays, were used to determine the amount of virus in each well. RT assays were used for wild-type and resistant isolates of strains 89-959 and SF162 grown in PBMCs. RT activity was measured on day 7 by methods similar to those described by Potts (20) . Our assays differed in several respects. A 20-l sample of supernatant from each well of the culture plate was transferred to a well in another plate containing 50 l of RT assay cocktail. The cocktail substrates were 0.25 U of poly(rA)⅐p(dT) [12] [13] [14] [15] [16] [17] [18] (Pharmacia) per ml and 0.3 M [ 3 H]TTP (25 Ci/ml; New England Nuclear), and the assay mixture was incubated at 37ЊC for 2 to 4 h. A Tomtec cell harvester was used to transfer the contents of the RT assay wells onto DEAE-treated glass fiber filters (Wallac), and the radioactivity was counted in a Betaplate 1205 scintillation counter (Wallac/Pharmacia). The concentration of p24 antigen was measured in a kinetic assay (Coulter Corporation) for clones created by oligonucleotide-mediated sitedirected mutagenesis and grown in MT2 cells. LAI isolates grown in CEM cells were assayed by using p24 reduction, as described by Richman et al. (23) . Data from both RT and p24 assays were used to determine EC 50 s by fitting the four-parameter logistic model (8) to the data by using the SAS nonlinear modeling procedure (PROC NLIN).
Construction of proviral clones and characterization of mutated HIV-1. Oligonucleotide-mediated site-directed mutagenesis of the protease gene and the production of infectious mutated viruses was done by the methods described by Potts et al. (21) . Mutated protease genes were made in HXB2gpt2 (HXB2) by using the Altered Sites In Vitro Mutagenesis System (Promega). Proviral clones were used to produce infectious virus via transfection of SW480 cells in the presence of Lipofectin (Gibco BRL). The growth rates of the mutated viruses with 88S, 88D, 10F, or 10F/88S in the protease were measured in cultures in the absence of drug over a 24-day period. MT2 cells were infected with equal concentrations of the mutated viruses, and cultures were sampled and fed fresh medium every 4 days. Cultures used for dose-response assays were also sampled and fed fresh medium and drug dilutions every 4 days. Comparisons among all the results from dose-response assays for the mutated and wild-type viruses were made by using the EC 50 of AZT, which was not affected by the protease mutations, as a standard.
Molecular modeling of compounds. Molecular modeling of SC-55389A and SC-52151 in the wild-type or mutated active sites was done by using Insight software from Biosym. Modeling was based on a crystal structure of the SC-55389A-wild-type HIV protease complex (11) and on the combined elements of SC-52151-related inhibitor-protease complexes. Mutations at position 88 were modeled by replacing the asparagine side chain with a serine or aspartic acid side chain possessing standard bond lengths and angles. Conformations of the side chain were evaluated by inspection of hydrogen-bonding geometries and avoidance of close contacts.
RESULTS
Selection of SC-55389A-resistant variants. Serial passage of a clinical strain (strain 89-959) and a laboratory strain (strain LAI) of HIV-1 in the presence of SC-55389A resulted in the selection of variants with reduced susceptibility to the drug. A moderate reduction (3 to 30 times) in susceptibility to SC-55389A was noted at passage 9 for strain 89-959 and passage 21 for LAI (Table 1 ). The predicted amino acid sequences of the proteases from independently sequenced DNA clones are presented in Fig. 3 . The sequences of wild-type 89-959 and LAI proteases differed from the consensus sequence for clade B (North American isolates) at several positions, and most of the resistant isolates retained those differences. Clones derived from 89-959 P9-55389A (the clone designation indicates that virus strain 89-959 was passaged nine times in the presence of SC-55389A) all acquired an additional substitution of serine for asparagine at amino acid 88 (N88S) (Fig. 3) . The N88S substitution, accompanied by L10F, was also exhibited by SC-55389A-resistant LAI P21-55389A (Fig. 3) . Thus, the N88S mutation was the only consistent change noted in all of the SC-55389A-resistant isolates examined, regardless of the selection strategy (slow escalation of drug concentration with LAI or a rapid selection starting at a high drug concentration with 89-959). These results suggested that the N88S mutation is involved in conferring the resistance phenotype.
The susceptibilities of variants with the N88S mutation (89-959 P9-55389A) to other protease inhibitors including SC- 52151 and the structurally distinct inhibitors L735,524 and Ro31-8959 are presented in Table 1 . Clone 89-959 P9-55389A retained wild-type susceptibility to SC-52151, L735,524, and Ro31-8959. Interestingly, SC-414, which is also structurally distinct, inhibited the replication of 89-959 P9-55389A at concentrations significantly lower than those that were effective against the wild-type virus population ( Table 1 ). The N88S substitution did not appear to be particularly disadvantageous since it remained predominant in the population after 26 passages in the absence of SC-55389A (Fig. 3) . SC-55389A resistance was also retained (Table 1 ). An additional substitution, M46I, was observed in all isolates after 17 passages in the absence of SC-55389A and persisted in 89-959 P9-55389A-P26-UT (Fig. 3) . Selection of HIV-1 variants resistant to SC-55389A, SC-52151, and other protease inhibitors. HIV-1 protease can tolerate multiple mutations conferring resistance to diverse protease inhibitors (7) . Selection experiments performed with the hydroxyethylurea isostere inhibitors SC-55389A and SC-52151 in sequence resulted in the selection of variants with crossresistance to protease inhibitors of several classes. Strain 89-959 P9-55389A was grown in escalating concentrations of both SC-55389A and SC-52151. After 26 passages, the 89-959 P9-55389A-P26-52151 virus population exhibited high-level resistance to SC-52151 (Table 1) , remained resistant to SC-55389A, and exhibited cross-resistance to Ro31-8959 and SC-414. Sensitivity to L735,524, however, was retained ( Table 1 ). The genotype of this cross-resistant virus population was found to be significantly changed from that of the parental strain. Whereas 89-959 P9-55389A had only the single consistent change, N88S, 89-959 P9-55389A-P26-52151 isolates had substitutions at multiple sites in the protease. Most notably, a change at posi- Selections that were made with SC-52151 and the monocytotropic HIV-1 strain SF162 yielded a variant that had a moderate shift (10 times) in susceptibility to SC-52151 (Table 1) . This variant (SF162 P80-52151) was obtained only after extensive passage in the presence of increasing concentrations of SC-52151. Interestingly, the wild-type SF162 isolate exhibited increased susceptibility to SC-55389A, L735,524, and Ro31-8959 compared with that observed for 89-959 (Table 1) . Sequence analysis of protease from the SF162 wild-type isolate revealed divergence from the consensus amino acid sequence of clade B protease at positions 11 (V to I), 63 (L to P), and 82 (V to I) (Fig. 3) . With the exception of the V11I substitution, which reverted to the consensus amino acid, all of these changes were present in the SC-52151-resistant virus SF162 P80-52151. In addition, the following changes were observed in SF162 P80-52151: N88D (three of three clones), A71V (three of three clones), F53L (three of three clones), M46I (three of three clones), and Q92R (one of three clones) (Fig. 3) . SF162 P80-52151 exhibited wild-type susceptibility to SC-55389A and L735,524 and a moderate (six times) reduction in sensitivity to Ro31-8959 ( Table 1 ). All of these changes were retained after 17 passages in the absence of drug, except for a V71T substitution (nine of nine clones) and the addition of a minor population of isolates with I54L (two of nine clones) and V77A (one of nine clones) substitutions. Although drug resistance was not assayed at passage 17, SC-52151 resistance was retained after 24 passages in the absence of drug (data not shown).
Titers of the working stocks of mutant viruses were low, and it was not possible to perform replicate assays for each virus and all the compounds listed in Table 1 with the same viral stock. Replicate assays were performed with several stocks, which were all grown from the same parent stock. Stocks were presumed to contain virus of the same genotype, but not all of the stock cultures were also used for sequence determinations. When data from three or more assays existed, the mean EC 50 s and standard deviations were calculated (see Table 1 and below). Values were 50 Ϯ 12 nM for SC-52151 and 856 Ϯ 552 nM for SC-55389A with 89-959 P9-55389A, 874 Ϯ 693 nM for SC-55389A with 89-959 P9-55389A-P26-UT, and 886 Ϯ 443 nM for SC-52151 with SF162 P80-52151. Analysis of the precision of the EC 50 estimates with replicate values for several compounds and viruses showed that the coefficient of variation for a single assay was less than 75%. Thus, the probability is 95% that the EC 50 from a single assay is within 2.5 times of the estimated value.
Characterization of mutated viruses created by oligonucleotide-mediated site-directed mutagenesis of an infectious proviral clone. Because the N88S mutation was the only consistent change observed during selections with SC-55389A alone, this mutation was introduced into an HXB2 proviral clone. Protease mutants were also constructed with an N88D substitution because SC-52151 resistance in both 89-959 P9-55389A-P26-52151 and SF162 P80-52151 correlated with the substitution of aspartic acid for the existing amino acid at position 88. The effects of these mutations on the growth characteristics of HXB2 were determined (Fig. 4). Cluster analysis (1, 24) , performed with data consisting of estimates of the day at which maximum growth was achieved and reached a plateau, showed that only the strain with 10F alone grew like the wild type. Strains with 88S, 10F/88S, and 88D clustered together. These data suggest that substitution of either S or D for N at position 88 is tolerable but less advantageous than the wild-type sequence. The introduction of a second site mutation in the 88S variant corresponding to 10F, which was also predominant in LAI P21-55389A and 89-959 P9-55389A-P26-52151, but which was not observed in 89-959 P9-55389A (Fig. 2) , did not restore wild-type growth (Fig. 4) . Indeed, in the HXB2 background, the L10F mutation appeared to be silent in terms of growth characteristics (Fig. 4) .
The role of the mutations in drug resistance, determined by dose-response assays, is presented in Table 2 . Variants containing 88S alone or in conjunction with 10F exhibited comparable levels of resistance to SC-55389A (20 to 30 times). These mutations had no effect upon the potency of SC-52151, L735,524, Ro31-8959, or the AZT control. This phenotype is very similar to that observed for the passaged viruses ( Table 1 ), suggesting that 88S alone is responsible for resistance to SC-55389A. In contrast, the N88D and the L10F mutations alone had no effect on the resistance of HXB2 to SC-52151 or any of the other compounds analyzed ( Table 2) .
The role of mutations at residue 88 predicted by molecular modeling. The ribbon diagram of the SC-55389A-HIV protease complex (Fig. 5) shows the positions of the mutations observed during viral selection. Residue 88, which is important for protease susceptibility to SC-55389A, lies in a helix near the S2 and S2Ј subsites. Figures 6A and B SC-55389A to the S2 and S2Ј subsites. The side chains of the N residues at positions 88 on the two chains of the enzyme stabilize loops in the S2 and S2Ј subsites that are formed by amino acid residues that span positions 28 to 32. In particular, N88 in each subunit is positioned near the N termini of the only helices in the protease structure and through main chain and side chain interactions forms hydrogen bonds with T31 and D29 in the same subunit. In addition, the side chain of N88 interacts with T74 of the same subunit, and one of the interactions is mediated by hydrogen bonds to a solvent that is conserved in crystal structures. Mutation of N88 to serine would disrupt all of the interactions stabilized by side chain hydrogen bonds from this residue, including those that stabilize the conformation of the loop between residues 28 and 32. Mutation of N88 to aspartic acid could preserve the hydrogen bonds to T31, but their strength would be altered and this could lead to subtle changes in the conformation of the loop at residues 28 to 32. The N88D mutation would likewise perturb the interactions with T74, and unless the D side chain is protonated and some of the hydrogen donor-acceptor roles with solvent are reversed, it is likely that this interaction would not be preserved.
DISCUSSION
Mutations at position 88 in the HIV-1 protease gene were observed after passaging three different virus strains in three separate experiments in the presence of hydroxyethylurea inhibitors. One of these compounds, SC-55389A, was used against two different strains and resistant variants from both strains had the same mutation to serine at position 88. In one case (virus strain 89-959 P9-55389A) this was the only consistent change observed that was not present in the wild type. In strain LAI P21-55389A, the second change at position 10 is in a variable region of the molecule. It probably did not contribute to the resistance phenotype since the viral strain created by oligonucleotide-mediated site-directed mutagenesis in HXB2 containing only 10F behaved like the wild type. In contrast, HXB2 with the 88S mutation alone or with the 10F-88S mutation combination exhibited resistance to SC-55389A inhibition similar to that for LAI P21-55389A. Clearly, position 88 plays a key role in the interaction between SC-55389A and the protease molecule. This position may also influence interactions of the enzyme with other inhibitors, since isolates with the N88S mutation had greater susceptibility than the wild type to inhibition by SC-414.
The role of position 88 in the enzyme's interaction with SC-52151 is less clear. Although a mutation to aspartic acid was observed in resistant viral isolates (SF162 P80-52151 and 89-959 P9-55389A-P26-52151) after passaging two different strains in SC-52151, this mutation was never observed by itself in a resistant strain. Of all the changes observed in these resistant mutants, N88D was of particular interest because it was in the same position as the crucial N88S change observed in the other two strains; however, when 88D alone was created by oligonucleotide-mediated site-directed mutagenesis in HXB2, the virus was not resistant to SC-52151 or any of the other compounds tested. The resistance to SC-52151 exhibited by the selected strain (SF162 P80-52151) could have been achieved through one of the other observed changes or the cooperative effects of some or all of them.
Determining EC 50 s from dose-response assay data taken at only one time point was not adequate for assessing the relative potencies of compounds against viral populations with different growth characteristics. This was true for viruses that were obtained both by selections and by oligonucleotide-mediated site-directed mutagenesis. To ensure that the comparisons of protease inhibitor EC 50 s obtained with different viral strains were accurate, we determined the times postinfection when the AZT EC 50 s for those strains matched (see Table 2 ).
Mutations in position 88 have not been reported to occur after in vitro selection with other protease inhibitors (7, 18, 25). In patients, the N88S mutation was sometimes found in viral populations after treatment with indinavir (5). N88S and N88D mutations were also observed in the context of some other mutations in viral populations from patients treated with nelfinavir (19) .
The substitutions that we observed at residue 88 have not been previously described in HIV-1, but they are known to occur in other retroviruses. The asparagine residue at position 88 in the wild-type HIV-1 enzyme lies within a helix that is structurally conserved. The corresponding carboxy-terminal sequence G-A-D/N (residues equivalent to those at positions 86 to 88 in HIV-1) is unique to retroviral aspartic proteases and occurs in HIV-1, HIV-2, simian immunodeficiency virus, feline immunodeficiency virus, equine infectious anemia virus (EIAV), visna virus, Moloney murine leukemia virus, baboon endogenous virus, human T-cell leukemia virus types 1 and 2, and Rous sarcoma virus (26) . Only the three primate viruses (HIV-1, HIV-2, and simian immunodeficiency virus) have an N at residue 88. All the others listed above have a D at residue 88. Interestingly, feline immunodeficiency virus and EIAV have been tested against many protease inhibitors developed for HIV, and are resistant to nearly all of them, including SC-52151 and SC-55389A (22; unpublished data). Both viruses differ from HIV-1 at several other aa positions that have been shown to be associated with resistance (7), including residue 88. Any of these differences could contribute to the observed resistance to HIV-1 protease inhibitors. However, Powell et al. (22) showed that the difference between EIAV and HIV proteases at the residue equivalent to residue 48 in HIV is not solely responsible for the resistance of the EIAV protease to HIV protease inhibitors, since making an I48G change in the EIAV enzyme did not increase its susceptibility to the drugs. Other oncoviruses, visna virus, and caprine arthritis encephalitis virus differ from HIV-1 at residue 88. All except bovine immunodeficiency-like virus have a D residue; bovine immunodeficiency-like virus has an S residue. A better understanding of the role played by residue 88 in interactions with protease inhibitors and natural substrates may be gained through study of these divergent proteases.
Mutational analyses have shown that certain substitutions at Residues 28 to 32 form a loop that defines a significant portion of the S2Ј subsite. The P1Ј isoamyl group of the inhibitor is surrounded by hydrophobic side chains that include A28 and V32 as well as isoleucine residues at positions 47 and 84 (data not shown). The conformation of the loop between residues 28 and 32 is stabilized by hydrogen bonds (dashed lines) from both main chain and side chain atoms of residues R87 and N88. The side chain amide oxygen of the N88 side chain accepts protons in hydrogen bonds with the side chain hydroxyl (2.8 Å) and the main chain nitrogen (3.35 Å) of T31 in the loop. The main chain nitrogen of N88 is hydrogen bonded to the carbonyl of D29 (3.3 Å), and the main chain nitrogen of R87 is hydrogen bonded to the carbonyl of A28 (2.8 Å). The guanidinium group of R87 and the carboxyl group of D29 interact ionically via hydrogen bonding geometry with an N . . . O separation of 2.8 Å. The side chain amide nitrogen of N88 also interacts with T74 by hydrogen bonding which is in part mediated through interactions with a conserved solvent. When SC-52151 is bound to the protease, it is anticipated from crystal structures (11) that the P1Ј isobutyl group will be bound in the S2Ј subsite. (B) Binding of SC-55389 in the S2 subsite of HIV protease. Residues 28 to 32 from the opposing chain (labelled b) also form a loop whose conformation is stabilized by a similar, although not identical, network of hydrogen bonds with R87b and N88b. The P2 t-butyl group of the inhibitor is shown bound in this subsite; the N-methyl group of the inhibitor also forms a hydrogen bond with the carboxyl group of D29b. When SC-52151 is bound to the protease, it is anticipated from crystal structures (11) that the P2 carboxamide moiety will be bound in this subsite, in part through hydrogen bonding interactions with the carboxyl group of D30b. residue 87 or 88 render the enzyme completely inactive (16, 27) and that residue 88 is involved in dimer formation (12, 27) . X-ray crystal structures of hydroxyethylurea inhibitors bound to recombinant HIV-1 protease suggest that the side chains of N residues at position 88 stabilize the conformation of residues 28 to 32, which form substantial parts of the S2 and S2Ј subsites by forming hydrogen bonds to residues 29 and 31. Amino acid substitutions at position 88 could alter the conformations of these loops and thereby modulate the enzyme's affinity for an inhibitor.
The mutations that we observed after selection with a single drug persisted after many passages in the absence of drug, suggesting that the altered genotypes were stable in the absence of selection pressure, even though viruses with the 88S or 88D mutation appeared to be less competent. We also observed that mutations accumulated with additional selection pressure, either from higher concentrations of a single drug or with the addition of another drug. Furthermore, selections with SC-55389A and SC-52151 were simultaneously done with wild-type strain 89-959 in parallel with the 26 passages with 89-959 P9-55389A. Although resistant virus was isolated from the latter selection, no resistant virus emerged from the wildtype cultures before the experiment was terminated after 26 passages (data not shown). These three observations suggest that sequential treatment regimens with combinations of protease inhibitors will mediate the emergence of cross-resistant virus more readily than concurrent treatment with drug combinations. Combinations of drugs should be chosen so that mutants resistant to either single drug are not cross-resistant to the other drug. For example, viruses selected for resistance to SC-55389A were still highly susceptible to protease inhibitors of different chemical classes (L735,524, Ro31-8959, and SC-414). Preferably, investigators will identify combinations of drugs in which mutants resistant to either single drug are even more sensitive to the second drug, such as SC-55389A and SC-414, or the combinations reported by Tisdale et al. (25) . Such combinations, as well as those with inhibitors of other viral functions, should exert an enduring suppression of HIV replication.
